IL15 and acute myeloid leukemia: An IL-15-incorporated NKCE against acute myeloid leukaemia (AML), referred to as CLEC12A TriKE or CD16axIL-15xCLEC12A (Table 2), has been shown to specifically expand NK cells, but not T cells, leading to the potent killing of AML cells by NK cells (61).